Clene(CLNN) - 2025 Q1 - Quarterly Results

CLENE REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS AND RECENT OPERATING HIGHLIGHTS SALT LAKE CITY, May 7, 2025 -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, "Clene") and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced its first quarter 2025 financial results and provided recent upda ...